| An aryl hydrocarbon receptor agonist that is being developed by Dermavant Sciences Inc. (a subsidiary of Roivant Sciences Inc.) as a topical treatment for plaque psoriasis and atopic dermatitis |
| Received its first approval on 23 May 2022 in the USA |
| Approved for the topical treatment of plaque psoriasis in adults |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.